Methods| All kidney transplant recipients followed up in the outpatient Kidney Transplantation
Department of Strasbourg University Hospital between January 20, 2021, and June 3, …

2 (SARS-CoV-2) have not been specifically investigated in kidney transplant recipient (KTRs).
Preliminary results suggest that among KTRs who received the first injection of an mRNA-…

To the editor: Several of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
vaccines use a nucleosidemodified, purified mRNA lipid nanoparticle-encapsulated …

The cilgavimab−tixagevimab combination retains a partial in vitro neutralizing activity against
the current SARS‐CoV‐2 variants of concern (omicron BA.1, BA.1.1, and BA.2). Here, we …

Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has spread widely, causing
coronavirus disease 2019 (COVID‐19) and significant mortality. However, data on viral …

Transplant recipients, who receive therapeutic immunosuppression to prevent graft rejection,
are characterized by high coronavirus disease 2019 (COVID-19)–related mortality and …

BK virus (BKV) replication occurs frequently in kidney transplant recipients (KTR), potentially
leading to BKV‐associated nephropathy (BKVAN) and graft loss. Patients with high titers of …

A recent study demonstrated that a single dose of a severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) mRNA-based vaccine is sufficient to mount a robust immunological …

Background. Data on coronavirus disease 2019 (COVID-19) in immunocompromised kidney
transplant recipients (KTR) remain scanty. Although markers of inflammation, cardiac injury, …

In this study, we show, for the first time, a significant decrease of the anti-RBD IgG 4 to 5
months after the administration of 150 mg of tixagevimab and 150 mg of cilgavimab. The …